Building AgomAb

Driven to lead a paradigm shift in regenerative diseases

AgomAb is pioneering therapies that modulate regenerative pathways to achieve structural tissue repair and functional organ recovery. Our growing pipeline of highly specific monoclonal antibodies is designed to treat a range of acute and chronic conditions that involve inflammatory, metabolic and fibrotic processes. By combining new scientific insights with robust development expertise, we are building a company to lead to the emergence of truly regenerative medicines.

Chief Executive Officer
Chief Scientific Officer
Chief Development Officer
Chief Medical Officer
Chief Business Officer
Chief Financial Officer
General Counsel
Board of Directors
Chairman of the Board
Chief Executive Officer

Become a partner or investor.

We further aim to combine our internal scientific and development expertise with leading partners to expand our therapeutic programs and combine strengths to meet some of the most pressing needs in medicine.